Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
CONTINUED EXAMINATIONS
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/4/2026 has been entered.
Applicant’s amendment in the reply filed on 7/15/26 is acknowledged. Claims 1-15, and 17 are pending. Claims 11-15 are withdrawn. Claims 1-10, and 17 are examined on the merits.
Any rejection that is not reiterated is hereby withdrawn.
Claim Rejections –35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim 17 is newly rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Yu et al (CN 108210975 A).
This is a new rejection necessitated by the Applicant’s amendment filed on 7/15/26.
Yu et al teach a dressing liquid for treating acne, characterized in that the dressing liquid is mainly composed of 1 to 10 parts of marine hydrolyzed collagen (thus at least one protenaceous amino acid), 0.5 to 4 parts of dipotassium glycyrrhizinate, 0.2 to 1 part of aloe vera gel powder (thus claim 10 is met, thus an active agent), and prepared by 1000 parts of water (see claim 1). Yu et al teach the dressing liquid according to claim 1, wherein the molecular weight of said marine hydrolyzed collagen (thus claim 1 is met) is 400~1500 Daltons, such as 400 Daltons, 500 Daltons, 600 Daltons (thus the claimed 500-1000Da), 700 Daltons, 800 Daltons, 900 Daltons, 1000 Daltons, 1100 Daltons, 1200 Daltons, 1300 Daltons, or 1400 Daltons (see claim 3).
Yu et al teach in the half-face experiment, both individuals used the dressing described in Example 4 of this invention on the right half of their face (thus cosmetic, thus claim 9 is met), while the left half of their face served as a control [0090].
Yu et al teach acne can persist for years, causing disfigurement or leaving permanent scars and having a serious negative impact on a patient's psychological [0004].
Yu et al teach marine hydrolyzed collagen with the claimed low molecular weight has inhibitory strength on tyrosinase activity [0068] (thus the claimed limitation of “consisting of” is met).
Therefore, the reference is deemed to anticipate the instant claim above.
Claim Rejections –35 USC § 103
The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
(a) A patent may not be obtained through the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
Claim 17 is newly rejected under 35 U.S.C. 103(a) as being unpatentable over Yu et al (CN 108210975 A).
This is a new rejection necessitated by the Applicant’s amendment filed on 7/15/26.
Yu et al teach a dressing liquid for treating acne, characterized in that the dressing liquid is mainly composed of 1 to 10 parts of marine hydrolyzed collagen, 0.5 to 4 parts of dipotassium glycyrrhizinate, 0.2 to 1 part of aloe vera gel powder, and prepared by 1000 parts of water (see claim 1). Yu et al teach the dressing liquid according to claim 1, wherein the molecular weight of said marine hydrolyzed collagen (thus claim 1 is met) is 400~1500 Daltons, such as 400 Daltons, 500 Daltons, 600 Daltons (thus the claimed 500-1000Da, thus a low molecular weight hydrolyzed collagen), 700 Daltons, 800 Daltons, 900 Daltons, 1000 Daltons, 1100 Daltons, 1200 Daltons, 1300 Daltons, or 1400 Daltons (see claim 3).
Yu et al teach in the half-face experiment, both individuals used the dressing described in Example 4 of this invention on the right half of their face, while the left half of their face served as a control [0090].
Yu et al teach acne can persist for years, causing disfigurement or leaving permanent scars and having a serious negative impact on a patient's psychological [0004].
Yu et al teach marine hydrolyzed collagen with the claimed low molecular weight has inhibitory strength on tyrosinase activity [0068].
The teachings of Yu et al do not specifically teach “consisting of” in the acne treating composition.
It would have been prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to use marine hydrolyzed collagen with the claimed range of low molecular weight to inhibit tyrosinase activity since Yu et al teach marine hydrolyzed collagen with the claimed low molecular weight has inhibitory strength on tyrosinase activity.
From the teachings of the references, it is apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention.
Thus, the invention as a whole is prima facie obvious over the references, especially in the absence of evidence to the contrary.
Conclusion
Claims 1-10 are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Qiuwen Mi/
Primary Examiner, Art Unit 1655
Prosecution Insights